306 related articles for article (PubMed ID: 28371937)
1. A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.
Webster LR; Yamada T; Arjona Ferreira JC
Pain Med; 2017 Dec; 18(12):2350-2360. PubMed ID: 28371937
[TBL] [Abstract][Full Text] [Related]
2. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
Hale M; Wild J; Reddy J; Yamada T; Arjona Ferreira JC
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
[TBL] [Abstract][Full Text] [Related]
3. Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: results from 2 randomized, placebo-controlled, phase 3 trials.
Wild J; Yamada T; Arjona Ferreira JC; Hale M
Pain; 2019 Oct; 160(10):2358-2364. PubMed ID: 31145214
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.
Katakami N; Harada T; Murata T; Shinozaki K; Tsutsumi M; Yokota T; Arai M; Tada Y; Narabayashi M; Boku N
J Clin Oncol; 2017 Dec; 35(34):3859-3866. PubMed ID: 28968171
[TBL] [Abstract][Full Text] [Related]
5. Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study.
Webster LR; Nalamachu S; Morlion B; Reddy J; Baba Y; Yamada T; Arjona Ferreira JC
Pain; 2018 May; 159(5):987-994. PubMed ID: 29419653
[TBL] [Abstract][Full Text] [Related]
6. Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer.
Katakami N; Oda K; Tauchi K; Nakata K; Shinozaki K; Yokota T; Suzuki Y; Narabayashi M; Boku N
J Clin Oncol; 2017 Jun; 35(17):1921-1928. PubMed ID: 28445097
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of naldemedine for the treatment of opioid-induced constipation: A meta-analysis.
Esmadi M; Ahmad D; Hewlett A
J Gastrointestin Liver Dis; 2019 Mar; 28(1):41-46. PubMed ID: 30851171
[TBL] [Abstract][Full Text] [Related]
8. Randomized, Double-Blind Trial of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.
Rauck R; Slatkin NE; Stambler N; Harper JR; Israel RJ
Pain Pract; 2017 Jul; 17(6):820-828. PubMed ID: 27860208
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age.
Wild J; Webster L; Yamada T; Hale M
Drugs Aging; 2020 Apr; 37(4):271-279. PubMed ID: 32086791
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of naldemedine for the treatment of opioid-induced constipation.
Song X; Wang D; Qu X; Dong N; Teng S
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):121-128. PubMed ID: 30652502
[TBL] [Abstract][Full Text] [Related]
11. Naldemedine for the treatment of opioid-induced constipation in adults with chronic noncancer pain.
Liu JJ; Quinton SE; Brenner DM
Pain Manag; 2020 Sep; 10(5):301-306. PubMed ID: 32552565
[TBL] [Abstract][Full Text] [Related]
12. Naldemedine: A Review in Opioid-Induced Constipation.
Blair HA
Drugs; 2019 Jul; 79(11):1241-1247. PubMed ID: 31267482
[TBL] [Abstract][Full Text] [Related]
13. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation.
Webster L; Dhar S; Eldon M; Masuoka L; Lappalainen J; Sostek M
Pain; 2013 Sep; 154(9):1542-1550. PubMed ID: 23726675
[TBL] [Abstract][Full Text] [Related]
14. Naldemedine versus placebo in opioid-induced constipation: a meta-analysis.
Wobbe B; Gerner M; Köhne CH
BMJ Support Palliat Care; 2024 Jan; 13(e3):e578-e584. PubMed ID: 36517204
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer.
Katakami N; Harada T; Murata T; Shinozaki K; Tsutsumi M; Yokota T; Arai M; Tada Y; Narabayashi M; Boku N
Ann Oncol; 2018 Jun; 29(6):1461-1467. PubMed ID: 32151367
[TBL] [Abstract][Full Text] [Related]
16. Naldemedine is effective in the treatment of opioid-induced constipation in patients with chronic non-cancer pain who had a poor response to laxatives.
Hale ME; Wild JE; Yamada T; Yokota T; Tack J; Andresen V; Drewes AM
Therap Adv Gastroenterol; 2021; 14():17562848211032320. PubMed ID: 34377150
[TBL] [Abstract][Full Text] [Related]
17. A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain.
Cryer B; Katz S; Vallejo R; Popescu A; Ueno R
Pain Med; 2014 Nov; 15(11):1825-34. PubMed ID: 24716835
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain.
Jamal MM; Adams AB; Jansen JP; Webster LR
Am J Gastroenterol; 2015 May; 110(5):725-32. PubMed ID: 25916220
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid Class.
Webster LR; Brewer RP; Lichtlen P; Losch-Beridon T; Mareya S; Wang M
Pain Med; 2018 Jun; 19(6):1195-1205. PubMed ID: 29897589
[TBL] [Abstract][Full Text] [Related]
20. Treatment with Naloxegol Versus Placebo: Pain Assessment in Patients with Noncancer Pain and Opioid-Induced Constipation.
Webster L; Diva U; Tummala R; Sostek M
Pain Pract; 2018 Apr; 18(4):505-514. PubMed ID: 28898536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
